Journal
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
Volume 11, Issue 5, Pages 553-563Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/1744666X.2015.1026894
Keywords
adenosine; dihydrofolate reductase inhibitor; folic acid; methotrexate; methotrexate polyglutamates; pharmacogenetics; psoriasis
Categories
Ask authors/readers for more resources
In the era of biologic therapies, methotrexate (MTX), a classic immunomodulator, is still the cornerstone of systemic treatment of psoriasis. MTX has been used for many years, achieving good responses with a good safety profile. However, only a few randomized clinical trials have been performed involving MTX, and most of the current evidence comes from pivotal studies of biologic drugs. The aim of this article is to make an extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available